Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Second generation TKIs in chronic myeloid leukaemia

EHA 2011

Published: 11 Jun 2011

Views: 6698

Rating:

Save

Prof Timothy Hughes - Institute of Medical and Veterinary Science, Adelaide, Australia

Because it is not necessary to use second-generation tyrosine kinase inhibitors front-line for all patients with chronic myeloid leukaemia, and molecular criteria have now been defined to guide decisions about if and when to use dasatinib or nilotinib. These come from the TIDEL II study data released at the EHA meeting. Tim Hughes tells ecancer tv about molecular response rates to initial therapy with imatinib which indicate when to switch therapy. Using these indicators the group has confirmed that first use of imatinib — with delayed introduction of second generation agents — is equivalent in effectiveness to using dasatinib or nilotinib as initial therapy.

Related Videos

Understanding cognitive impairment for elderly patients undergoing CAR T therapy

Dr Ashley Rosko - The Ohio State University, Columbus, USA

Understanding cognitive impairment for elderly patients undergoing CAR T therapy ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )

SIOG 2024: Updates in haematology

Dr Ashley Rosko - The Ohio State University, Columbus, USA

SIOG 2024: Updates in haematology ( Dr Ashley Rosko - The Ohio State University, Columbus, USA )

Expectations and priorities of older patients with cancer: the PRIORITY multicenter cohort study

Dr Camille Chakiba - Institute Bergonié, Bordeaux, France

Expectations and priorities of older patients with cancer: the PRIORITY multicenter cohort study ( Dr Camille Chakiba - Institute Bergonié, Bordeaux, France )

New classification for identifying HR myeloma based on cytogenetic abnormalities

Dr Jill Corre - IUCT Oncopole, Toulouse, France

New classification for identifying HR myeloma based on cytogenetic abnormalities ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM

Dr Jill Corre - IUCT Oncopole, Toulouse, France

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Use of bispecifics and CAR T cells in South America

Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

Use of bispecifics and CAR T cells in South America ( Dr Natalia Schütz - Hospital Italiano de Buenos Aires, Buenos Aires, Argentina )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer